Tilt also reported a net loss of $12.6 million in the quarter versus a net loss of $8.7 million in the prior year period. At ...

Top-line data for its phase 2b trial studying GH001 is expected either in the fourth quarter of 2024 or the first quarter of ...

Vancouver-based C21 Investments Inc. (CSE: CXXI) (OTCQX: CXXIF) bucked state cannabis market trends with a 14% sequential ...

A coalition of 120 craft cannabis farmers in New York filed suit against the state’s marijuana regulators this week, claiming ...

Social media and former professional poker player Dan Bilzerian is suing his father Paul Bilzerian and Ignite Brands over ...

Regulators outlined recommendations and rules related to creating a safe working environment for those working with cannabis.

The firm expects to report its 12-month phase 2 data next week, with topline results from a phase 3 trial anticipated in 2026 ...

Management said the company completed its first harvest in New Jersey, with initial product expected to hit the market in ...

The company attributed the increase to accelerated revenue growth in Germany, which reached C$4.3 million, and decreased net ...

CV Sciences Inc. (OTCQB: CVSI) reported third-quarter revenue of $3.9 million, down 5% from the year-ago period, according to ...

Rubicon is forecasting continued growth through the end of 2024. Rubicon said that despite continued price competitiveness ...

The CBD maker said state-level changes in hemp laws as public health concerns rise are impeding attempts to expand its retail ...